Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea

Launched by MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD · May 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat vivax malaria, a type of malaria that's harder to eliminate because it can hide in the liver and cause repeated infections. The researchers want to see if a shorter treatment with a medicine called primaquine, combined with quick testing for a genetic condition called G6PD deficiency, is more effective and easier for patients to follow than the standard longer treatment. G6PD deficiency can cause serious side effects when taking primaquine, so testing is important to keep patients safe.

To participate in this study, you need to have vivax malaria and be at least one year old. However, if you're pregnant, breastfeeding, or have certain health issues like low hemoglobin levels or a history of bad reactions to primaquine, you won't be eligible to join. If you take part, you can expect to receive education about the treatment, support during your care, and follow-up checks to ensure everything goes smoothly. This trial aims to improve malaria treatment and make it easier for people to stick to their medicine, ultimately helping to control malaria in Papua New Guinea.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with vivax malaria
• Exclusion Criteria:
• • Patients who are pregnant
• • Patients who are breastfeeding
• • Patients with a Hb \<8g/dL
• • Patients with a previous adverse reaction to primaquine
• • Patient with severe malaria